Vernon K Sondak Selected Research

Neoplasms (Cancer)

4/2024	First-in-human stage III/IV melanoma clinical trial of immune priming agent IFx-Hu2.0.
9/2023	Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma.
1/2023	Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
12/2022	Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
12/2022	Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
9/2022	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study.
1/2022	Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
1/2022	Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
1/2022	Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
1/2022	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vernon K Sondak Research Topics

Disease

160	Melanoma (Melanoma, Malignant) 04/2024 - 01/2002
86	Neoplasms (Cancer) 04/2024 - 01/2002
33	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2002
11	Merkel Cell Carcinoma 01/2022 - 05/2002
7	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2012
6	Brain Neoplasms (Brain Tumor) 01/2018 - 01/2010
5	Skin Neoplasms (Skin Cancer) 01/2022 - 11/2008
5	Basal Cell Carcinoma (Rodent Ulcer) 01/2022 - 01/2011
5	Sarcoma (Soft Tissue Sarcoma) 02/2012 - 04/2004
4	Disease Progression 03/2023 - 05/2005
4	Infections 01/2021 - 01/2016
3	Diarrhea 01/2023 - 11/2008
3	Extranodal Extension 12/2022 - 06/2018
3	Carcinoma (Carcinomatosis) 01/2021 - 05/2003
3	Papillomavirus Infections 01/2016 - 11/2008
2	Exanthema (Rash) 09/2023 - 01/2021
2	Fatigue 01/2023 - 02/2015
2	Neoplasm Micrometastasis 12/2022 - 07/2005
2	COVID-19 01/2022 - 01/2021
2	Uveal melanoma 11/2020 - 01/2012
2	Nausea 02/2015 - 10/2010
2	Anemia 02/2015 - 01/2005
2	Leukemia 11/2014 - 04/2004
1	Acute Kidney Injury (Acute Renal Failure) 09/2023
1	Chronic Disease (Chronic Diseases) 01/2023

Drug/Important Bio-Agent (IBA)

18	IpilimumabIBA 10/2023 - 11/2008
14	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2023 - 04/2009
13	InterferonsIBA 01/2023 - 01/2002
13	Biomarkers (Surrogate Marker)IBA 06/2022 - 09/2006
11	VemurafenibIBA 09/2023 - 07/2011
11	VaccinesIBA 10/2014 - 01/2002
10	AntigensIBA 12/2022 - 01/2002
9	Interleukin-2 (IL2)IBA 01/2022 - 06/2003
9	Proteins (Proteins, Gene)FDA Link 04/2016 - 06/2003
9	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 02/2002
7	pembrolizumabIBA 10/2023 - 01/2017
6	Dacarbazine (DIC)FDA LinkGeneric 03/2015 - 04/2004
5	NivolumabIBA 10/2023 - 01/2017
5	Interferon alpha-2 (Roferon-A)FDA Link 01/2023 - 03/2002
5	Immune Checkpoint InhibitorsIBA 12/2022 - 10/2019
4	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 01/2003
4	AntibodiesIBA 01/2021 - 06/2013
4	LigandsIBA 03/2015 - 12/2008
4	Phosphotransferases (Kinase)IBA 12/2014 - 04/2004
4	Histocompatibility Antigens Class IIBA 10/2014 - 04/2002
4	MelacineIBA 10/2014 - 04/2002
4	Cancer VaccinesIBA 06/2003 - 01/2002
4	Peptides (Polypeptides)IBA 06/2003 - 01/2002
3	RNA (Ribonucleic Acid)IBA 09/2023 - 01/2021
3	InterleukinsIBA 01/2022 - 12/2008
3	Messenger RNA (mRNA)IBA 10/2019 - 08/2013
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2017 - 09/2004
3	Cisplatin (Platino)FDA LinkGeneric 11/2014 - 04/2004
3	ORALIT (ORS)IBA 05/2014 - 08/2012
3	Mitogen-Activated Protein KinasesIBA 01/2014 - 01/2012
3	Hematoxylin (Haematoxylon)IBA 10/2010 - 05/2002
3	Eosine Yellowish-(YS) (Eosin)IBA 10/2010 - 05/2002
3	Imatinib Mesylate (Gleevec)FDA Link 10/2010 - 01/2008
3	HLA Antigens (Human Leukocyte Antigens)IBA 09/2010 - 10/2002
2	cobimetinibIBA 09/2023 - 11/2020
2	Small Cytoplasmic RNAIBA 01/2022 - 01/2021
2	Viral DNAIBA 01/2021 - 01/2021
2	dabrafenibIBA 11/2020 - 12/2016
2	trametinibIBA 11/2020 - 01/2018
2	Keratins (Keratin)IBA 01/2020 - 05/2003
2	Vinblastine (Vinblastine Sulfate)FDA Link 11/2014 - 12/2008
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2014 - 01/2005
2	HLA-A2 Antigen (HLA A2 Antigen)IBA 10/2014 - 04/2002
2	tyrosine receptor (receptor, tyrosine)IBA 07/2014 - 02/2005
2	Carboplatin (JM8)FDA LinkGeneric 05/2014 - 01/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 05/2014 - 01/2012
2	Type 1 Melanocortin ReceptorIBA 08/2013 - 12/2012
2	Small Interfering RNA (siRNA)IBA 06/2013 - 04/2011
2	ErbB Receptors (EGF Receptor)IBA 05/2013 - 02/2005
2	Coloring Agents (Dyes)IBA 02/2013 - 01/2013
2	Sorafenib (BAY 43-9006)FDA Link 02/2012 - 01/2012
2	Thalidomide (Thalomid)FDA Link 01/2010 - 11/2007
2	Indicators and Reagents (Reagents)IBA 07/2009 - 02/2008
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 07/2008 - 01/2003
2	Protein Subunit VaccinesIBA 01/2003 - 01/2002
1	Histones (Histone)IBA 02/2024
1	ChromatinIBA 02/2024
1	relatlimabIBA 10/2023
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 09/2023
1	CTLA-4 AntigenIBA 04/2023

Therapy/Procedure

91	Therapeutics 12/2023 - 01/2002
29	Immunotherapy 12/2022 - 01/2002
20	Lymph Node Excision (Lymph Node Dissection) 01/2023 - 01/2003
16	Drug Therapy (Chemotherapy) 01/2018 - 02/2002
12	Radiotherapy 01/2022 - 09/2007
7	Neoadjuvant Therapy 03/2023 - 01/2017
5	Chemoprevention 01/2019 - 03/2005
2	Metastasectomy 01/2024 - 08/2012
2	Cell- and Tissue-Based Therapy (Cell Therapy) 12/2022 - 01/2018
2	Adjuvant Radiotherapy 06/2020 - 05/2014
2	Biological Therapy 11/2014 - 05/2011
2	Palliative Care (Palliative Therapy) 01/2010 - 07/2007
1	Intralesional Injections 04/2024
1	Drug Tapering 09/2023
1	Molecular Targeted Therapy 08/2023